News
VIRX
3.670
-5.41%
-0.210
Viracta Therapeutics President and Chief Executive Officer Dr. Ivor Royston Receives the Science History Institute's Biotechnology Heritage Award
Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that its President and Chief Executive Officer, Ivor Royston, M.D., is being presented with the Science History Institute's Bio...
PR Newswire · 06/13 20:15
DBV, Rubius top healthcare gainers; Rigel, Cosmos lead losers' pack
Gainers: DBV Technologies (DBVT) +21%. Rubius Therapeutics (RUBY) +20%. Annovis Bio (ANVS) +17%. LumiraDx (LMDX) +16%. CTI BioPharma (CTIC) +15%. Losers: Rigel Pharmaceuticals (RIGL) -48%. Cosmos (COSM) -13%. Accelerate Diagnostics (AXDX) -9%. Omeros (OMER...
Seekingalpha · 06/08 14:02
Viracta Therapeutics Provides An Update On The Phase 1B/2 Trial Of Nana-val In Patients With Advanced Epstein-barr Virus-positive (EBV+) Solid Tumors And Announces Upcoming Poster Presentation At The ASCO Annual Meeting
 Viracta Therapeutics, Inc. (NASDAQ:VIRX), a precision oncology company targeting virus-associated malignancies, today announced that the Safety Monitoring Committee for the ongoing Phase 1b/2 study of
Benzinga · 06/02 12:31
Viracta Therapeutics Provides an Update on the Phase 1b/2 Trial of Nana-val in Patients with Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors and Announces Upcoming Poster Presentation at the ASCO Annual Meeting
Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that the Safety Monitoring Committee for the ongoing Phase 1b/2 study of Nana-val in patients with EBV+ solid tumors (VT3996-30...
PR Newswire · 06/02 12:30
Viracta Therapeutics To Progress to Next Dose Level in Nana-val Trial
MT Newswires · 06/02 12:10
Viracta Therapeutics to Present at the Jefferies Healthcare Conference
Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company management is scheduled to present at the Jefferies Healthcare Conference on Thursday, June 9, 2022, at 1:30 p.m. ...
PR Newswire · 06/01 20:15
SQZ Biotechnologies names Marshelle Smith Warren as chief medical officer
SQZ Biotechnologies (NYSE:SQZ) has appointed Marshelle Smith Warren as chief medical officer, effective June 1. She was previously CMO and SVP, R&D at Viracta Therapeutics (VIRX). She has also served as
Seekingalpha · 05/31 21:20
Enlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman
Former Worldwide Head of Licensing and Acquisition and Knowledge Management at Merck & Co., where he led the completion of more than150 business development transactions Former Global Head of Infectious Diseases for Johnson & Johnson Pharmaceuticals Former...
GlobeNewswire · 05/23 12:00
Stocks That Hit 52-Week Lows On Monday
  On Monday, 198 companies reached new 52-week lows.
Benzinga · 05/16 17:59
Viracta Therapeutics to Present at Upcoming May Investor Conferences
Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company management will present and participate in one-on-one meetings at the following investor conferences in May:
PR Newswire · 05/11 20:05
Viracta Therapeutics to Host Key Opinion Leader Webinar on Nana-val for the Treatment of Advanced Epstein-Barr Virus-Positive Solid Tumors
Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, will host a key opinion leader (KOL) webinar on Nana-val (nanatinostat and valganciclovir) for the treatment of advanced Epstein-Barr virus-pos...
PR Newswire · 04/20 15:58
VIRX, ARQQ and GWGH among mid-day movers
Gainers: Casa Systems (CASA) +67%. CEL-SCI Corporation (CVM) +55%. Natus Medical (NTUS) +29%. Frequency Therapeutics (FREQ) +26%. GWG Holdings (GWGH) +20%. IMARA (IMRA) +19%. Iveda Solutions (IVDA) +18%. AgriFORCE (AGRI) +18%. Maris-Tech
Seekingalpha · 04/18 16:37
34 Stocks Moving In Monday's Mid-Day Session
Gainers Casa Systems, Inc. (NASDAQ: CASA) shares climbed 66.3% to $6.47 after the company announced a multi-year contract with Verizon to provide 5G core network functions.
Benzinga · 04/18 16:13
CTRM, VIRX and CYTO among mid-day movers
Gainers: Veru (VERU) +196%. Hoth Therapeutics (HOTH) +126%. Altamira Therapeutics (CYTO) +54%. Iveda Solutions (IVDA) +37%. VNET Group (VNET) +30%. SailPoint Technologies Holdings (SAIL) +29%. Castor Maritime (CTRM) +25%. Datto
Seekingalpha · 04/11 16:44
Viracta Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company leadership is scheduled to present at the 21st Annual Needham Virtual Healthcare Conference, on Wednesday, April 1...
PR Newswire · 04/07 14:13
Viracta Therapeutics Announces New Employment Inducement Grant
Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that the Compensation Committee of Viracta's Board of Directors approved the grant of non-qualified stock options to a new non-...
PR Newswire · 03/18 20:10
Viracta Therapeutics GAAP EPS of -$0.31 beats by $0.02
Viracta Therapeutics press release (NASDAQ:VIRX): Q4 GAAP EPS of -$0.31 beats by $0.02. Cash balance of $103.6 million as of December 31, 2021.
Seekingalpha · 03/16 12:56
BRIEF-Viracta Therapeutics Reports Q4 And Full Year 2021 Financial Results
reuters.com · 03/16 12:31
Viracta Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference
Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company leadership is scheduled to participate in a fireside chat at the 32nd Annual Oppenheimer Healthcare Conference, on...
PR Newswire · 03/09 21:30
What Type Of Shareholders Own The Most Number of Viracta Therapeutics, Inc. (NASDAQ:VIRX) Shares?
A look at the shareholders of Viracta Therapeutics, Inc. ( NASDAQ:VIRX ) can tell us which group is most powerful...
Simply Wall St. · 02/22 16:35
More
Webull provides a variety of real-time VIRX stock news. You can receive the latest news about Viracta Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About VIRX
Viracta Therapeutics, Inc., formerly Sunesis Pharmaceuticals, Inc., is a precision oncology company. The Company is focused on the development of new medicines targeting virus-associated malignancies. The Company conducts clinical trials for its combination product candidate as a therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The Company is conducting three clinical trials for its lead product candidate, Nana-val, in EBV+ lymphomas and solid tumors, including a Phase II registrational trial of Nana-val in EBV+ lymphomas. Its lead product candidate is an all-oral combination of nanatinostat. Its development pipeline also includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor and VRx-510, a preclinical-stage PDK-1 inhibitor. Its novel synthetic lethality approach targets the EBV genome to enable the killing of the tumor cells by inducing the expression of certain viral kinase genes which in-turn activate an antiviral drug.